Honest conversation, shared experience, and time to ask the questions that no one else has time to answer. To receive the link to this Friday's meeting, email me.
Common questions about prostate cancer answered honestly and in plain language. From the questions patients and families ask me most often in clinic.
Prostate cancer is a malignancy that begins in the prostate gland — a walnut-sized organ in men that sits below the bladder and surrounds the upper part of the urethra. The prostate makes part of the fluid that becomes semen.
Most prostate cancers start in the glandular cells of the prostate. Most grow slowly. Some grow quickly and aggressively. A central job of modern prostate cancer care is telling the difference — and treating accordingly.
Prostate cancer is the most common non-skin cancer in men. About one in eight men will be diagnosed in his lifetime. It is overwhelmingly a disease of older men — the median age at diagnosis is around 67.
Risk is higher in men of African descent, in those with a family history of prostate, breast, ovarian, or pancreatic cancer, and in those carrying certain inherited gene mutations (such as BRCA1/2 and Lynch syndrome).
Most prostate cancers are hormone-driven — they depend on testosterone to grow — and their underlying biology is relatively indolent. Many men diagnosed with very-low-risk or low-risk disease would die of something else before their prostate cancer caused them any harm.
This is why active surveillance — careful monitoring instead of immediate treatment — is now standard for selected patients with low-risk disease.
Early prostate cancer usually has no symptoms. By the time symptoms appear, the disease is often more advanced. This is one reason screening exists.
When symptoms do occur, they may include changes in urination (slow stream, urgency, getting up at night), blood in the urine or semen, erectile dysfunction, or pain in the bones (especially the back, hips, or pelvis) in advanced cases. None of these are specific to prostate cancer — they have many other causes — but they're worth bringing up with your doctor.
Most prostate cancers are curable, particularly when caught at a localized stage. Cure rates for localized disease — meaning cancer that has not spread outside the prostate — exceed 95% with appropriate treatment.
Even in cases where the cancer has spread (metastatic disease), modern treatments often allow men to live many years with good quality of life. The goal in these cases is long-term control rather than cure, but that distinction matters less and less as treatments improve.
PSA stands for prostate-specific antigen — a protein made by the prostate gland that circulates in your blood. The PSA test measures the level of this protein in a simple blood draw.
A higher PSA can indicate prostate cancer, but it can also be elevated by benign conditions like an enlarged prostate (BPH), prostatitis (inflammation), recent ejaculation, or vigorous bicycle riding. Interpreting PSA requires context — your age, your previous values, the rate of change, and other factors all matter.
Major guidelines now recommend a personalized approach. In general:
The most important thing is a shared decision with a physician who knows you. Screening is not a one-size-fits-all recommendation.
There is no single cutoff that defines "normal." Historically, PSA below 4 ng/mL was considered normal, but this is a rough guide. Many men with prostate cancer have PSAs below 4. Many men with PSAs above 4 do not have cancer.
More important than a single value is the trend over time, your age (PSA rises naturally with age), the size of your prostate, and other factors. A urologist or radiation oncologist familiar with prostate cancer can put your number in context.
Not necessarily. An elevated PSA is a signal to investigate further — but most men with elevated PSAs do not turn out to have prostate cancer.
Next steps after an abnormal PSA usually include repeating the test (to rule out a transient cause), a physical exam, possibly additional blood tests (free PSA, PHI, 4Kscore), and often an MRI of the prostate before deciding whether a biopsy is needed.
A prostate biopsy is the procedure that confirms (or rules out) prostate cancer. A urologist inserts a thin needle into the prostate — typically guided by ultrasound — and takes small tissue samples that are then examined by a pathologist under a microscope.
Increasingly, biopsies are done with MRI guidance, which improves the chance of finding clinically significant cancer while reducing the chance of finding insignificant disease that would never have caused harm. Modern biopsies are usually done as an outpatient procedure with local anesthesia or sedation.
The Gleason score describes how aggressive prostate cancer looks under the microscope. It's the single most important prognostic factor in newly diagnosed prostate cancer.
It is calculated by adding the two most common patterns of cancer in the biopsy. Each pattern is graded 1 to 5. A typical report reads something like "Gleason 3+4=7" or "Gleason 4+3=7" — and the order matters. A 3+4 is meaningfully less aggressive than a 4+3, even though both add up to 7.
Modern reports also use Gleason Grade Groups (1 to 5), which simplify interpretation. Grade Group 1 is the least aggressive; Grade Group 5 is the most aggressive.
Staging is the process of determining how far the cancer has spread. It guides treatment choice and predicts outcomes.
Prostate cancer is staged using the TNM system: T describes the local tumor, N whether lymph nodes are involved, and M whether there are distant metastases. Staging combines exam findings, PSA, Gleason score, and imaging results.
For the patient, the practical distinction often comes down to: localized disease (confined to the prostate), locally advanced (spread to nearby tissues or lymph nodes), or metastatic (spread to distant organs or bones). Each calls for a different treatment approach.
Risk stratification groups men with newly diagnosed prostate cancer into categories — very low, low, favorable intermediate, unfavorable intermediate, high, and very high risk — based on PSA, Gleason score, and clinical stage.
Risk category drives almost every treatment decision: who can safely consider active surveillance, who needs aggressive treatment, who needs hormone therapy alongside radiation, who might benefit from additional imaging or genomic testing. Knowing your risk category is the foundation for any meaningful conversation about treatment.
PSMA PET (prostate-specific membrane antigen PET) is a modern imaging test that has transformed prostate cancer staging and monitoring. It uses a radioactive tracer that binds specifically to prostate cancer cells, making them visible on imaging.
PSMA PET is more sensitive than traditional CT or bone scans for detecting prostate cancer that has spread. It is particularly useful in higher-risk newly diagnosed patients and in men with rising PSA after surgery or radiation. Not every patient needs one — your doctor will tell you whether your case warrants one.
Active surveillance is the practice of carefully monitoring low-risk prostate cancer instead of treating it immediately. It is not "doing nothing" — it is a structured program of regular PSA tests, periodic exams, imaging, and repeat biopsies designed to catch any progression early enough to treat with curative intent.
For appropriately selected men with very-low-risk or low-risk prostate cancer, active surveillance allows them to avoid the side effects of immediate treatment while keeping cure on the table if the cancer ever shows signs of becoming more aggressive.
For the right patients, yes — and the evidence supporting this has only strengthened over the past decade. Large studies have shown that men with low-risk prostate cancer on careful surveillance have excellent long-term cancer outcomes, with most never requiring treatment.
Safety depends on patient selection and on disciplined follow-up. Surveillance done poorly — missed visits, skipped biopsies, inadequate imaging — is not safe surveillance. Done well, it is one of the most important advances of the last twenty years in prostate cancer care.
Surveillance ends when there is evidence that the cancer has progressed and treatment is now appropriate. Signs of progression include: a rising PSA trend, a higher Gleason score on a follow-up biopsy, more biopsy cores involved with cancer, or new findings on MRI.
Surveillance may also end if a patient simply decides they want treatment — anxiety about an untreated cancer is real, and it's a legitimate reason to choose treatment even without disease progression. There is no wrong choice here; it's a personal decision.
For localized prostate cancer, the main options are:
For appropriately selected patients, surgery and radiation give similar long-term cancer control. The differences are in side effect profiles, recovery time, and personal preference.
For most patients with localized prostate cancer, the answer is: neither is clearly better in terms of cancer control. Multiple high-quality studies have shown comparable long-term survival between surgery and radiation when both are done by experienced providers in appropriately selected patients.
The differences are in how patients are affected. Surgery tends to cause more immediate effects on urinary continence and erectile function. Radiation tends to cause more long-term bowel and urinary effects, and a small increase in the risk of bladder or rectal cancer many years later. The right answer depends on your individual situation, preferences, and what you most want to preserve.
Brachytherapy is internal radiation therapy. Tiny radioactive sources are placed directly into the prostate, delivering a high dose of radiation to the cancer while sparing surrounding tissues. There are two main types:
Brachytherapy can be used alone for selected patients or combined with external beam radiation for higher-risk patients. It is one of my clinical specialties.
Hormone therapy — also called androgen deprivation therapy (ADT) — reduces the male hormone testosterone, which fuels prostate cancer growth. It does not cure prostate cancer on its own, but it slows cancer growth and improves the effectiveness of radiation in higher-risk disease.
ADT is used in several settings: combined with radiation for intermediate- and high-risk localized disease, as a primary treatment for advanced disease, and after surgery or radiation if the cancer comes back. Duration ranges from months to years depending on risk and stage.
ADT has significant side effects — hot flashes, fatigue, muscle loss, bone thinning, mood changes, sexual dysfunction, metabolic effects. These deserve careful discussion before starting treatment.
Proton therapy is a form of radiation that uses protons instead of x-rays. In theory, it can deposit its dose more precisely. In practice, for prostate cancer, randomized data have not shown that protons offer meaningful clinical advantages over modern x-ray techniques.
Proton therapy is significantly more expensive and is offered at relatively few centers. For most patients with prostate cancer, modern external beam radiation, SBRT, or brachytherapy provide equivalent outcomes at far lower cost and with greater geographic access.
Clinical trials are how cancer care advances. They are not experiments on you — they are carefully designed studies that often offer access to promising new treatments before they are widely available.
If a clinical trial fits your situation, it is worth seriously considering. Ask your treating team whether any open trials are appropriate for your case. National databases (like ClinicalTrials.gov) list trials worldwide.
Side effects depend heavily on which treatment you receive. The most common ones across treatments are:
Most side effects improve substantially over time. Many can be reduced with modern techniques and good supportive care. They should be discussed honestly before any treatment decision.
Many men worry about incontinence — and many fewer experience permanent severe incontinence than they fear. Rates depend on the treatment, your baseline function, and the experience of your surgeon or radiation team.
After surgery, most men experience some leakage in the weeks after the operation. Most regain full continence within a year. A small percentage have persistent stress incontinence that may need additional treatment (pads, a sling, or an artificial sphincter).
After radiation, severe incontinence is rare. Mild urgency and frequency are more common, especially in the months after treatment.
Sexual function after prostate cancer treatment is one of the most important — and most under-discussed — concerns. Honest discussion is essential before treatment.
Erectile dysfunction is common after both surgery and radiation. It tends to occur sooner after surgery (immediately, with gradual improvement over 1–2 years) and more gradually after radiation (declining over the first several years). Many men recover function with medications (PDE5 inhibitors), injections, vacuum devices, or surgical implants.
Baseline function matters: men who had good erections before treatment do better afterward than men whose function was already declining. So does age and overall health.
Yes. The most important predictor of side effects is the experience of your treating team — high-volume centers with experienced surgeons and radiation oncologists consistently have better outcomes. So choosing where you go matters.
Other things that help:
There is no diet that has been proven to cure prostate cancer. But a heart-healthy diet — rich in vegetables, fruits, whole grains, and lean protein, with limited red meat and processed foods — is good for overall health and may modestly slow prostate cancer progression.
Maintaining a healthy weight, regular exercise, and not smoking are far more important than any specific food or supplement. Be cautious about unproven supplements and "alternative" cancer diets — many are expensive, unstudied, and some can interact with treatments.
A rising PSA after surgery or radiation is called biochemical recurrence. It is a signal that some prostate cancer cells may still be present — somewhere — and producing PSA. It does not mean immediate danger, and it does not mean treatment failure.
The next steps depend on how high the PSA is, how fast it's rising, your original disease characteristics, and how long it's been since treatment. Some recurrences are best treated immediately; others can be watched. Modern imaging like PSMA PET helps identify where the cancer might be, which guides treatment.
Treatment options depend on where the recurrence is and your initial treatment:
This is a fast-moving area of prostate cancer medicine. New treatments and combinations are emerging regularly.
Increasingly, yes — especially if you have:
Testing for inherited mutations (especially BRCA1, BRCA2, and Lynch syndrome genes) can affect your treatment options — some treatments work especially well in patients with these mutations — and it provides important information for your children and other relatives.
If you have prostate cancer, your sons, brothers, and other first-degree male relatives are at modestly higher risk and should start screening earlier (often at age 40–45 rather than 50).
If genetic testing reveals an inherited mutation, the implications are broader — your daughters' risk of breast and ovarian cancer may be affected, and other relatives may benefit from testing themselves. This is a good reason to have a serious conversation with a genetic counselor if you carry one of these mutations.
Your first visit — the consultation — is a conversation. We review your diagnosis, your imaging and pathology, the recommendations you have received so far, and we discuss whether radiation therapy is the right choice for your situation. We talk through what treatment would involve, what realistic outcomes look like, and what side effects you would face. There is no obligation to begin treatment from this visit.
Before radiation begins, we perform a simulation — a planning session, not a treatment. You lie on a CT scanner in the exact position you will be in for treatment, and we use the scan to design where the radiation will go and which tissues to spare. Most simulations take about thirty minutes. Small temporary markings or tiny tattoos may be placed on your skin to align you precisely each day.
The treatment itself is painless — you cannot see, hear, or feel the radiation as it is being delivered. Side effects may develop over the course of treatment, but the actual delivery of radiation is silent and sensation-free. Most daily treatment sessions take only a few minutes.
Only if your scalp is being treated. Radiation only affects hair in the area being treated. Radiation for prostate cancer, for example, does not cause head hair loss.
Often, no. Nausea depends on the part of the body being treated. Radiation to the upper abdomen can cause it; radiation to the prostate alone rarely does. When nausea is expected, medications can usually prevent or control it.
For external beam radiation — the most common form — no. You can hug your family, hold babies, and interact normally between treatments and after the course is complete. For some forms of brachytherapy, brief precautions are needed; we will explain these in detail if they apply to your treatment.
Adaptive radiotherapy uses daily imaging on the treatment machine to refine the plan based on changes in your anatomy from day to day. AUBMC's Varian Ethos system is one of the few in the region capable of full adaptive treatment, which improves precision — especially for prostate cancer, where the position of the prostate and surrounding organs varies slightly each day.
The end of radiation is not the end of your care. Most side effects continue for several weeks after treatment finishes and gradually improve. Follow-up appointments — usually beginning around four to six weeks after treatment ends — monitor recovery, response, and long-term outcomes. For prostate cancer, regular PSA blood tests are an important part of follow-up.
I'm writing a book on prostate cancer for patients and their families — a single, trusted resource that goes deeper than anything I can fit on a website. Watch this page for its release.
Notify Me When It Launches